N-(2-((6-(3,5-Dimethyl-1H-pyrazol-1-yl)pyridazin-3-yl)amino)ethyl)-4-iodobenzenesulfonamide

Catalog No. :
ACMWIF735
CAS No. :
957508-62-2
Molecular Formula :
C17H19IN6O2S
Molecular Weight :
498.35

IUPAC Name:N-(2-((6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridazin-3-yl)amino)ethyl)-4-iodobenzenesulfonamide

N-(2-((6-(3,5-Dimethyl-1H-pyrazol-1-yl)pyridazin-3-yl)amino)ethyl)-4-iodobenzenesulfonamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(2-((6-(3,5-Dimethyl-1H-pyrazol-1-yl)pyridazin-3-yl)amino)ethyl)-4-iodobenzenesulfonamide
IUPAC NameN-(2-((6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridazin-3-yl)amino)ethyl)-4-iodobenzenesulfonamide
MDL No.MFCD09758731
Molecular FormulaC17H19IN6O2S
Molecular Weight498.35
SMILESCC1=NN(C2=NN=C(NCCNS(=O)(=O)C3=CC=C(I)C=C3)C=C2)C(C)=C1
InChI KeyCANRGRQDAOERKB-UHFFFAOYSA-N
SynonymN-(2-{[6-(3,5-dimethyl-1H-pyrazol-1-yl)-3-pyridazinyl]amino}ethyl)-4-iodobenzenesulfonamide
CAS No.957508-62-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACMWIF735 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFTVG210 route compound structure diagram
    ACFTVG21098-61-3 In Stock
  4. Then
  5. ACMWIF735 route product structure diagram
    ACMWIF735957508-62-2
Inquiry

2. ACMWIF735 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMWIF735 route product structure diagram
    ACMWIF735957508-62-2
Inquiry

Comments (0)